Back to Search
AMY HANCOCK, MD
MD
Geriatric Medicine (Family Medicine) Physician
NPI: 1790942225Individual
Specialties, Licenses & Credentials
Geriatric Medicine (Family Medicine) PhysicianPrimary
Family Medicine — Geriatric Medicine
Code: 207QG0300X
MD442716(PA)
Research & Publications (20)
Does 5-bromo-2'-deoxyuridine (BrdU) disrupt cell proliferation and neuronal maturation in the adult rat hippocampus in vivo?
PMID 19121338·Behav Brain Res·2009
7-preclinical
Investigations of the roles of arginine 115 and lysine 120 in the active site of 5,10-methenyltetrahydrofolate synthetase from Mycoplasma pneumoniae.
PMID 18473156·Protein J·2008
8-other
Adaptations to climate in candidate genes for common metabolic disorders.
PMID 18282109·PLoS Genet·2008
8-other
A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis.
PMID 17210670·Hum Mol Genet·2007
8-other
The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
PMID 16513092·Biochem Pharmacol·2006
6-review
Distinctions and contradistinctions between antiobesity histamine H(3) receptor (H (3)R) antagonists compared to cognition-enhancing H (3) receptor antagonists.
PMID 16547814·Inflamm Res·2006
7-preclinical
Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists.
PMID 15833055·Expert Opin Investig Drugs·2005
6-review
Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy.
PMID 15928821·Inflamm Res·2005
7-preclinical
Perspectives on cognitive domains, H3 receptor ligands and neurological disease.
PMID 15461554·Expert Opin Investig Drugs·2004
6-review
Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist.
PMID 15033391·Eur J Pharmacol·2004
7-preclinical
In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists.
PMID 15447739·Basic Clin Pharmacol Toxicol·2004
7-preclinical
Genetic and pharmacological aspects of histamine H3 receptor heterogeneity.
PMID 14550847·Life Sci·2003
6-review
H3 receptor antagonists/inverse agonists as anti-obesity agents.
PMID 14649210·Curr Opin Investig Drugs·2003
6-review
Microparticle column geometry in acoustic stationary fields.
PMID 12558301·J Acoust Soc Am·2003
8-other
Preclinical pharmacology of fiduxosin, a novel alpha(1)-adrenoceptor antagonist with uroselective properties.
PMID 11805207·J Pharmacol Exp Ther·2002
7-preclinical
Kinematic gait adaptations in unilateral transtibial amputees during rehabilitation.
PMID 19367517·Prosthet Orthot Int·2009
4-observational
Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships.
PMID 19588934·J Med Chem·2009
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 555 N DUKE ST
LANCASTER, PA 17602 - Phone
- (717) 544-4940
Quick Facts
- NPI
- 1790942225
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile